T-regulatory Cells in ALS (Tregs in ALS)
Phase 2a Study of the Expansion and Infusion of Autologous T-Regulatory Cells in Amyotrophic Lateral Sclerosis
Sponsor: Massachusetts General Hospital
A PHASE2 clinical study on ALS (Amyotrophic Lateral Sclerosis), this trial is ongoing. The trial is conducted by Massachusetts General Hospital and has accumulated 11 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Oct 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Nov 2021 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 6 earlier versions
-
May 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2020 — Apr 2020 [monthly]
Recruiting PHASE2
-
Oct 2019 — Jan 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2019 — Oct 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Aug 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Massachusetts General Hospital
- North East Amyotrophic Lateral Sclerosis Consortium
- The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston
- The Methodist Hospital Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .